Jaguar Health, Inc.

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 08/07/2025 am IST			5-day change	1st Jan Change
2.540 ^USD	-1.55%		+0.79%	-89.94%

25/06	Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	MT
11/06	Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	MT

Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment

Published on 27/08/2024 at 20:28, updated on 27/08/2024 at 20:29

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Jaguar Health, Inc.

Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	25/06	MT
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	11/06	MT
Jaguar Health Prices Offering of Shares, Warrants	21/05	MT
Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025	19/05
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Jaguar Health, Inc. - Special Call	30/04
Jaguar Health, Inc. and Napo Therapeutics Announce Initial Proof-Of-Concept Results	30/04	CI
Jaguar Health, Inc., Q4 2024 Earnings Call, Mar 31, 2025	31/03
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	31/03	CI
Jaguar Health, Inc. announced that it has received $3.4 million in funding	31/03	CI
Jaguar Health, Inc. Auditor Raises 'Going Concern' Doubt	31/03	CI
Sector Update: Health Care Stocks Lower Late Afternoon	27/03	MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	26/03	MT
Sector Update: Health Care	26/03	MT
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall	26/03	MT
Jaguar Health, Inc. announced that it expects to receive $3.4 million in funding	26/03	CI
Jaguar Health to Implement 1-for-25 Reverse Stock Split	18/03	MT
Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Enter into an Amendment with Streeterville Capital, LLC	21/02	CI
Jaguar Health, Inc., Q3 2024 Earnings Call, Nov 13, 2024	13/11
Earnings Flash (JAGX) JAGUAR HEALTH Posts Q3 Revenue $3.1M	13/11	MT
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs	06/11	CI
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024	24/24/24	CI
Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment	27/24/27	MT
Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods	19/24/19	MT

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Employees

Sector

Pharmaceuticals

Calendar

13/08 - Q2 2025 Earnings Release (Projected)

More about the company